Outlook Therapeutics, Inc. Common Stock (OTLK) Stock Price

OTLKStock

$0.64−77.28%52W

Market Cap$155.31M

P/E—

PEG Ratio—

Div yield—

Beta0.63

OTLK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)37.44%

Price vs S&P 500 (4W)-35.68%

VGM Score32.89

Book Value / Share (Quarterly)$0.82

P/TBV (Annual)13.70x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-22.93%

Cash Flow / Share (Quarterly)$-0.45

Price vs S&P 500 (YTD)-73.41%

Net Profit Margin (TTM)-1506.99%

EPS (TTM)$-1.26

10-Day Avg Trading Volume37.86M

EPS Excl Extra (TTM)$-1.26

Revenue Growth (5Y)-13.86%

EPS (Annual)$-1.79

ROI (Annual)-335.84%

Gross Margin (Annual)4.05%

Net Profit Margin (5Y Avg)-1724.56%

Cash / Share (Quarterly)$0.07

ROA (Last FY)-259.89%

EBITD / Share (TTM)$-1.06

Operating Margin (TTM)-1806.15%

Cash Flow / Share (Annual)$-2.87

P/B Ratio15.56x

P/B Ratio (Quarterly)26.67x

Net Income / Employee (Annual)$-3,672,100

EV / Revenue (TTM)111.70x

Net Interest Coverage (TTM)-190.32x

ROA (TTM)-300.62%

EV / EBITDA (TTM)2.79x

EPS Incl Extra (Annual)$-1.79

Current Ratio (Annual)0.63x

Quick Ratio (Quarterly)0.27x

3-Month Avg Trading Volume20.63M

52-Week Price Return-77.28%

Revenue / Employee (TTM)$25,000

Tangible BV / Share (Quarterly)$-0.02

P/S Ratio (Annual)115.42x

Asset Turnover (Annual)0.48x

52-Week High$3.39

Operating Margin (5Y Avg)-1772.52%

EPS Excl Extra (Annual)$-1.79

26-Week Price Return48.68%

Quick Ratio (Annual)0.35x

13-Week Price Return82.88%

Total Debt / Equity (Annual)1.25x

Current Ratio (Quarterly)0.54x

Enterprise Value$182.38M

Revenue / Share Growth (5Y)-72.88%

Asset Turnover (TTM)0.07x

Revenue / Employee (Annual)$83,100

Pretax Margin (Annual)-4525.99%

Cash / Share (Annual)$0.63

3-Month Return Std Dev200.72%

Net Income / Employee (TTM)$-3,585,700

ROE (Last FY)-756.01%

Net Interest Coverage (Annual)-164.02x

EPS Basic Excl Extra (Annual)$-1.79

Total Debt / Equity (Quarterly)3.04x

EPS Incl Extra (TTM)$-1.26

ROI (TTM)-163.27%

P/S Ratio (TTM)383.96x

Pretax Margin (5Y Avg)-1775.19%

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$0.04

Price vs S&P 500 (52W)-95.59%

Year-to-Date Return-61.46%

5-Day Price Return-13.00%

EPS Normalized (Annual)$-1.79

ROA (5Y Avg)-217.13%

Net Profit Margin (Annual)-4416.21%

Month-to-Date Return-37.64%

Cash Flow / Share (TTM)$-0.25

EBITD / Share (Annual)$-1.92

Operating Margin (Annual)-4744.24%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-2965.91%

LT Debt / Equity (Quarterly)2.02x

EPS Basic Excl Extra (TTM)$-1.26

P/B Ratio (Annual)31.58x

Inventory Turnover (TTM)0.44x

Pretax Margin (TTM)-1506.99%

Book Value / Share (Annual)$0.77

Price vs S&P 500 (13W)80.09%

Beta0.63x

Revenue / Share (TTM)$0.01

ROE (TTM)-415.51%

52-Week Low$0.16

vGradeD

gGradeF

mGradeC

vgmGradeD

OTLK Earnings Surprise History

Q2 25-0.44est. -0.39

Q3 25-0.29est. -0.25

Q4 25-0.22est. -0.17

Q1 26-0.17est. -0.12

Q2 26-0.09est. -0.07

OTLK Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

3.90

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
OTLKOutlook Therapeutics, Inc. Common Stock	D	F	C	$0.64
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Outlook Therapeutics, Inc. Common Stock

Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab-gamma), a monoclonal antibody for ophthalmic diseases. LYTENAVA has received marketing approval in the European Union and United Kingdom for wet age-related macular degeneration treatment. The company is pursuing additional indications for its lead therapy as a first-line anti-VEGF option.